JP2015511245A - ピリドピリミジノン系キナーゼ阻害薬 - Google Patents

ピリドピリミジノン系キナーゼ阻害薬 Download PDF

Info

Publication number
JP2015511245A
JP2015511245A JP2014558849A JP2014558849A JP2015511245A JP 2015511245 A JP2015511245 A JP 2015511245A JP 2014558849 A JP2014558849 A JP 2014558849A JP 2014558849 A JP2014558849 A JP 2014558849A JP 2015511245 A JP2015511245 A JP 2015511245A
Authority
JP
Japan
Prior art keywords
alkyl
amino
phenyl
pyrido
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014558849A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015511245A5 (https=
Inventor
ウッズ，キース
マストラッチオ，アンソニー
ライ，チュンチウ
ガンディー，ビラージクマール・ビー
ペニング，トーマス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc filed Critical AbbVie Inc
Publication of JP2015511245A publication Critical patent/JP2015511245A/ja
Publication of JP2015511245A5 publication Critical patent/JP2015511245A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2014558849A 2012-02-23 2013-02-22 ピリドピリミジノン系キナーゼ阻害薬 Pending JP2015511245A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261602163P 2012-02-23 2012-02-23
US61/602,163 2012-02-23
PCT/US2013/027265 WO2013126656A1 (en) 2012-02-23 2013-02-22 Pyridopyrimidinone inhibitors of kinases

Publications (2)

Publication Number Publication Date
JP2015511245A true JP2015511245A (ja) 2015-04-16
JP2015511245A5 JP2015511245A5 (https=) 2016-06-30

Family

ID=47757712

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014558849A Pending JP2015511245A (ja) 2012-02-23 2013-02-22 ピリドピリミジノン系キナーゼ阻害薬

Country Status (8)

Country Link
US (1) US9718821B2 (https=)
EP (1) EP2817308B1 (https=)
JP (1) JP2015511245A (https=)
CN (1) CN104271576A (https=)
CA (1) CA2864142A1 (https=)
ES (1) ES2606640T3 (https=)
MX (1) MX2014010176A (https=)
WO (1) WO2013126656A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190128673A (ko) * 2017-03-10 2019-11-18 알막 디스커버리 리미티드 Wee-1 키나아제 억제제로서 유용한 피리미도피리미디논
JP2022502438A (ja) * 2018-09-27 2022-01-11 貝達薬業股▲ふん▼有限公司Betta Pharmaceuticals Co., Ltd Ｆｇｆｒ４阻害剤及びその使用
JP2022523073A (ja) * 2019-01-29 2022-04-21 フォグホーン セラピューティクス インコーポレイテッド 化合物及びその使用
JP2024522304A (ja) * 2021-06-04 2024-06-13 アプレラ セラピューティクス、インク． Ｗｅｅ１キナーゼ阻害剤として有用なピリドピリミジン誘導体

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201306610D0 (en) 2013-04-11 2013-05-29 Almac Discovery Ltd Pharmaceutical compounds
GB201322602D0 (en) * 2013-12-19 2014-02-05 Almac Discovery Ltd Pharmaceutical compounds
MX382781B (es) * 2014-04-02 2025-03-13 Intermune Inc Piridinonas anti-fibroticas.
RU2690853C2 (ru) * 2014-09-02 2019-06-06 Пьер Фабр Медикамент Производные изохинолинона, полезные для лечения рака
GB201612095D0 (en) * 2016-07-12 2016-08-24 Almac Discovery Ltd Pharmaceutical compounds
CN109803968A (zh) * 2016-08-15 2019-05-24 辉瑞公司 吡啶并嘧啶酮cdk2/4/6抑制剂
WO2018133829A1 (zh) 2017-01-23 2018-07-26 南京明德新药研发股份有限公司 作为Wee1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮衍生物
US20200108074A1 (en) 2017-03-31 2020-04-09 Seattle Genetics, Inc. Combinations of chk1- and wee1- inhibitors
AU2018301837A1 (en) * 2017-07-13 2020-02-06 Syros Pharmaceuticals, Inc. Tam kinase inhibitors
CN109422754A (zh) * 2017-08-24 2019-03-05 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
US10807994B2 (en) 2017-10-09 2020-10-20 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
WO2019074979A1 (en) 2017-10-09 2019-04-18 Girafpharma, Llc HETEROCYCLIC COMPOUNDS AND USES THEREOF
DK3712150T3 (da) 2017-11-01 2024-07-29 Wuxi Biocity Biopharmaceutics Co Ltd Makrocyklisk forbindelse, der tjener som wee1-hæmmer, og anvendelser deraf
GB201800378D0 (en) * 2018-01-10 2018-02-21 Almac Discovery Ltd Pharmaceutical compounds
JP7481336B2 (ja) 2018-10-26 2024-05-10 ウーシー・バイオシティ・バイオファーマシューティクス・カンパニー・リミテッド Ｗｅｅ１阻害剤としてのピリミドピラゾロン類誘導体及びその使用
EP3943496A4 (en) 2019-03-22 2022-05-18 Shouyao Holdings (Beijing) Co., Ltd. Wee1 inhibitor and preparation and use thereof
CN113939296A (zh) 2019-04-09 2022-01-14 诺维逊生物股份有限公司 杂环化合物及其用途
CN113784968B (zh) 2019-04-30 2024-03-15 无锡智康弘义生物科技有限公司 Wee1抑制剂化合物的晶型及其应用
WO2021022163A2 (en) 2019-07-31 2021-02-04 Foghorn Therapeutics Inc. Compounds and uses thereof
US12528825B2 (en) 2020-01-29 2026-01-20 Foghorn Therapeutics Inc. Compounds and uses thereof
TW202144354A (zh) * 2020-03-27 2021-12-01 大陸商貝達藥業股份有限公司 Fgfr4抑制劑的鹽型、晶型及其用途
US12522607B2 (en) 2020-06-17 2026-01-13 Wigen Biomedicine Technology (shanghai) Co., Ltd. Substituted pyrazolo[3,4-d]pyrimidines as wee-1 inhibitors
US12551584B1 (en) 2020-12-07 2026-02-17 Actinium Pharmaceuticals, Inc. Lewis Y radioimmunotherapy for the treatment of cancer
AU2022265032A1 (en) 2021-04-30 2023-11-16 Wigen Biomedicine Technology (shanghai) Co., Ltd. Fused ring compound as wee-1 inhibitor, and preparation method therefor and use thereof
CN116462687B (zh) 2022-01-18 2025-01-07 江苏天士力帝益药业有限公司 Wee1抑制剂及其制备和用途
IL315441A (en) 2022-03-07 2024-11-01 Debiopharm Int Sa Treatment methods for small cell lung cancer
CN117402162A (zh) 2022-07-13 2024-01-16 江苏天士力帝益药业有限公司 Wee1抑制剂及其制备和用途
IL326854A (en) 2023-09-14 2026-04-01 Debiopharm Int Sa Combination of WEE1 inhibitor and PKMYT1 inhibitor
TW202541810A (zh) 2023-12-22 2025-11-01 瑞士商德彪製藥國際公司 治療實體腫瘤之方法
WO2025186213A1 (en) 2024-03-04 2025-09-12 Debiopharm International S.A. Combination of a wee1 inhibitor and a topoisomerase 1 inhibitor

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003528101A (ja) * 2000-03-06 2003-09-24 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー ５−アルキルピリド［２，３−ｄ］ピリミジンチロシンキナーゼ阻害剤
JP2007536370A (ja) * 2004-05-04 2007-12-13 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 療法薬としてのピロリル置換ピリド［２，３−ｄ］ピリミジン−７−オンおよびその誘導体
JP2009525292A (ja) * 2006-01-31 2009-07-09 エフ．ホフマン−ラ ロシュ アーゲー ７ｈ−ピリド［３，４−ｄ］ピリミジン−８−オン、それらの製造及びプロテインキナーゼ阻害剤としての使用
WO2010019637A1 (en) * 2008-08-12 2010-02-18 Smithkline Beecham Corporation Chemical compounds
WO2010063352A1 (en) * 2008-12-01 2010-06-10 Merck Patent Gmbh 2, 5-diamino-substituted pyrido [4, 3-d] pyrimidines as autotaxin inhibitors against cancer
WO2010067888A1 (en) * 2008-12-12 2010-06-17 Banyu Pharmaceutical Co.,Ltd. Dihydropyrimidopyrimidine derivatives
JP2010132689A (ja) * 2006-04-27 2010-06-17 Banyu Pharmaceut Co Ltd ジヒドロピラゾロピリミジノン誘導体
WO2014023385A1 (en) * 2012-08-07 2014-02-13 Merck Patent Gmbh Pyridopyrimidine derivatives as protein kinase inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633003A (en) * 1994-03-31 1997-05-27 Cantor; Jerome O. Use of intratracheally administered hyaluronic acid to ameliorate emphysema
SG10201407012XA (en) * 2009-10-29 2014-11-27 Genosco Kinase inhibitors
GB201306610D0 (en) * 2013-04-11 2013-05-29 Almac Discovery Ltd Pharmaceutical compounds

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003528101A (ja) * 2000-03-06 2003-09-24 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー ５−アルキルピリド［２，３−ｄ］ピリミジンチロシンキナーゼ阻害剤
JP2007536370A (ja) * 2004-05-04 2007-12-13 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 療法薬としてのピロリル置換ピリド［２，３−ｄ］ピリミジン−７−オンおよびその誘導体
JP2009525292A (ja) * 2006-01-31 2009-07-09 エフ．ホフマン−ラ ロシュ アーゲー ７ｈ−ピリド［３，４−ｄ］ピリミジン−８−オン、それらの製造及びプロテインキナーゼ阻害剤としての使用
JP2010132689A (ja) * 2006-04-27 2010-06-17 Banyu Pharmaceut Co Ltd ジヒドロピラゾロピリミジノン誘導体
WO2010019637A1 (en) * 2008-08-12 2010-02-18 Smithkline Beecham Corporation Chemical compounds
WO2010063352A1 (en) * 2008-12-01 2010-06-10 Merck Patent Gmbh 2, 5-diamino-substituted pyrido [4, 3-d] pyrimidines as autotaxin inhibitors against cancer
WO2010067888A1 (en) * 2008-12-12 2010-06-17 Banyu Pharmaceutical Co.,Ltd. Dihydropyrimidopyrimidine derivatives
WO2014023385A1 (en) * 2012-08-07 2014-02-13 Merck Patent Gmbh Pyridopyrimidine derivatives as protein kinase inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KH S SHIKHALIEV ET AL: "Annulation of a pyridine ring with vicinal ethoxycarbonyl(methyl)pyrimidines", RUSSIAN CHEMICAL BULLETIN, vol. 58(9), JPN6016036687, 2009, pages 1996 - 1999, ISSN: 0003404465 *
REGISTRY（STN）［ONLINE］, JPN7016002829, 12 July 2016 (2016-07-12), pages 1030518 - 03, ISSN: 0003404466 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190128673A (ko) * 2017-03-10 2019-11-18 알막 디스커버리 리미티드 Wee-1 키나아제 억제제로서 유용한 피리미도피리미디논
JP2020510040A (ja) * 2017-03-10 2020-04-02 アルマック・ディスカバリー・リミテッドＡｌｍａｃ Ｄｉｓｃｏｖｅｒｙ Ｌｉｍｉｔｅｄ Ｗｅｅ−１キナーゼ阻害剤として有用なピリミドピリミジノン
JP7244430B2 (ja) 2017-03-10 2023-03-22 アルマック・ディスカバリー・リミテッド Ｗｅｅ－１キナーゼ阻害剤として有用なピリミドピリミジノン
KR102605546B1 (ko) 2017-03-10 2023-11-22 알막 디스커버리 리미티드 Wee-1 키나아제 억제제로서 유용한 피리미도피리미디논
JP2022502438A (ja) * 2018-09-27 2022-01-11 貝達薬業股▲ふん▼有限公司Betta Pharmaceuticals Co., Ltd Ｆｇｆｒ４阻害剤及びその使用
JP7446287B2 (ja) 2018-09-27 2024-03-08 貝達薬業股▲ふん▼有限公司 Ｆｇｆｒ４阻害剤及びその使用
JP2022523073A (ja) * 2019-01-29 2022-04-21 フォグホーン セラピューティクス インコーポレイテッド 化合物及びその使用
JP2024522304A (ja) * 2021-06-04 2024-06-13 アプレラ セラピューティクス、インク． Ｗｅｅ１キナーゼ阻害剤として有用なピリドピリミジン誘導体

Also Published As

Publication number Publication date
CN104271576A (zh) 2015-01-07
EP2817308A1 (en) 2014-12-31
US20130225589A1 (en) 2013-08-29
WO2013126656A1 (en) 2013-08-29
EP2817308B1 (en) 2016-09-07
US9718821B2 (en) 2017-08-01
ES2606640T3 (es) 2017-03-24
MX2014010176A (es) 2014-11-10
CA2864142A1 (en) 2013-08-29

Similar Documents

Publication Publication Date Title
US9718821B2 (en) Pyridopyrimidinone inhibitors of kinases
JP5886326B2 (ja) 三環式キナーゼ阻害薬
US8716297B2 (en) Chemical entities to be used for Wee1 inhibition for the treatment of cancer
US9181239B2 (en) Pyridopyrimidinone inhibitors of kinases
US20130023523A1 (en) Pyridazino[4,5-d]pyrimidin-5(6h)-one inhibitors of kinases
EP2558459B1 (en) Phthalazin-(2h)-one inhibitors of kinases
EP2665724A1 (en) Bicyclic inhibitors of alk
EP2558469B1 (en) Pyrrolopyrazinone inhibitors of kinases
CA2824873A1 (en) Bicyclic carboxamide inhibitors of kinases

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160422

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160513

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160908

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160927

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161221

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170711